Skip to content

Clinical Data Collection in Breast Tomosynthesis (COBRIS)

Clinical Data Collection in Breast Tomosynthesis: COBRIS

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05914168
Acronym
COBRIS
Enrollment
150
Registered
2023-06-22
Start date
2023-02-15
Completion date
2024-02-29
Last updated
2023-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

The purpose of the study is to assess an image acquisition application for breast tomosynthesis in a clinical environment

Detailed description

After being informed about the study and potential risks, all patients giving written informed consent will undergo their routine mammography examination. One additional mammography view will be obtained with the investigational application and analyzed. Subject participation is expected to last no more than 30 minutes. After the mammography examination, subjects will be followed according to the hospital standard of care.

Interventions

Three dimensional mammography

Sponsors

GE Healthcare
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
35 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women aged 35 years or older; * Women referred for unilateral or bilateral 2D and 3D mammography; * Women able and willing to comply with study procedures; * Women able and willing to participate in this study who have signed and dated the informed consent form; and * Women surgically sterile or postmenopausal or, the possibility of pregnancy is ruled out based on a negative urine pregnancy test

Exclusion criteria

* Women who have been previously included in this study; or * Be a minor, protected adult, adult deprived of liberty by judicial or administrative decision, pregnant, parturient or a breastfeeding mother; or * Women with BRCA 1 or BRCA 2 gene mutation

Design outcomes

Primary

MeasureTime frameDescription
Data Collection1 yearCollect clinical breast images obtained with the investigational application.

Secondary

MeasureTime frameDescription
Assessment of Image Quality1 yearAssess image quality through subjective and open expert evaluation of patient motion, visibility of replication artefacts and visibility of clinical findings.

Countries

France

Contacts

Primary ContactJean-Paul Antonini
jean-paul.antonini@ge.com+33 6 87706729
Backup ContactRazvan Iordache
razvan.iordache@med.ge.com+ 33 6 14199082

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026